These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 39018512

  • 21. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW, TOPIC Study Group.
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
    Hauser SL, Zielman R, Das Gupta A, Xi J, Stoneman D, Karlsson G, Robertson D, Cohen JA, Kappos L.
    Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
    [Abstract] [Full Text] [Related]

  • 25. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M.
    Mult Scler; 2024 Jun; 30(7):833-842. PubMed ID: 38619037
    [Abstract] [Full Text] [Related]

  • 26. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
    Newsome SD, Mokliatchouk O, Castrillo-Viguera C, Naylor ML.
    Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
    [Abstract] [Full Text] [Related]

  • 27. Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.
    Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Poole EM, Robinson M, Gold R.
    Mult Scler Relat Disord; 2019 Jun; 31():157-164. PubMed ID: 31005729
    [Abstract] [Full Text] [Related]

  • 28. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G.
    Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
    Trippe BS, Shepherd MD, Coulter FC, Bhargava A, Brett J, Chu PL, Oyer DS.
    Curr Med Res Opin; 2012 Jul; 28(7):1203-11. PubMed ID: 22509859
    [Abstract] [Full Text] [Related]

  • 30. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 31. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
    Tilly G, Cadoux M, Garcia A, Morille J, Wiertlewski S, Pecqueur C, Brouard S, Laplaud D, Degauque N.
    Front Immunol; 2021 Feb 01; 12():730342. PubMed ID: 34721394
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
    McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF.
    Am J Clin Dermatol; 2019 Apr 01; 20(2):267-276. PubMed ID: 30471012
    [Abstract] [Full Text] [Related]

  • 33. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
    Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Brette S, Robinson M, Gold R, Teri-PRO Trial Group.
    Mult Scler Relat Disord; 2017 Oct 01; 17():107-115. PubMed ID: 29055438
    [Abstract] [Full Text] [Related]

  • 34. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
    Miller AE, O'Connor P, Wolinsky JS, Confavreux C, Kappos L, Olsson TP, Truffinet P, Wang L, D'Castro L, Comi G, Freedman MS, Teriflunomide Multiple Sclerosis Trial Group.
    Mult Scler; 2012 Nov 01; 18(11):1625-32. PubMed ID: 22723573
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
    Grill JD, Flournoy C, Dhadda S, Ernstrom K, Sperling R, Molina-Henry D, Tranotti K, Harris R, Kanekiyo M, Gee M, Irizarry M, Kramer L, Aisen P, Raman R.
    Ann Neurol; 2024 Feb 01; 95(2):288-298. PubMed ID: 37830926
    [Abstract] [Full Text] [Related]

  • 37. Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
    Lorefice L, Pilotto S, Fenu G, Cimino P, Firinu D, Frau J, Murgia F, Coghe G, Cocco E.
    J Neurol Sci; 2022 Jul 15; 438():120292. PubMed ID: 35605316
    [Abstract] [Full Text] [Related]

  • 38. [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
    Boyko AN, Alifirova VM, Lukashevich IG, Goncharova ZA, Greshnova IV, Zaslavsky LG, Kotov SV, Malkova NA, Mishin GN, Parshina EV, Poverennova IY, Prakhova LN, Sivertseva SA, Smagina IV, Totolyan NA, Trinitatsky YV, Trushnikova TN, Khabirov FA, Chefranova JY, Shchur SG, Dudin VA, Pokhabov DV, Artemeva AV, Eremeeva AV, Linkova YN, Zinkina-Orikhan AV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024 Jul 15; 124(4):86-96. PubMed ID: 38676683
    [Abstract] [Full Text] [Related]

  • 39. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE.
    Clin Ther; 2015 Oct 01; 37(10):2366-80. PubMed ID: 26365096
    [Abstract] [Full Text] [Related]

  • 40. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role.
    Tan H, Li X, Li Y, He F, ZhangBao J, Zhou L, Yang L, Zhao C, Lu C, Dong Q, Li H, Quan C.
    Front Immunol; 2024 Oct 01; 15():1343531. PubMed ID: 38558796
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.